Cadonilimab– Anti-PD-1/CTLA4 Bispecific Antibody

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).

Product Details
Species Reactivity	Human
Source	Mammalian cells
Host/Isotype	Human IgG1 (L234A/L235A) kappa
Class	Bispecific Antibody
Type	Recombinant Humanized
Conjugate	Unconjugated
Molecular Weight	198.64 kDa
Storage Condition	Store at -80°C for 2 years. Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws